遗传靶点对食管胃结合部癌治疗的影响。

Impact of genetic targets on cancer therapy in esophagogastric cancer.

机构信息

Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.

出版信息

Adv Exp Med Biol. 2013;779:55-65. doi: 10.1007/978-1-4614-6176-0_3.

Abstract

The treatment of esophagogastric cancer has been rapidly evolving in the past decade. New cytotoxic drugs and targeted agents have been integrated in the therapeutic paradigm. To better understand the tumor biology and to better utilize targeted agents, genetic alterations in esophagogastric cancer have been actively explored. For example, Her2/Neu amplification and expression were observed in gastric and gastroesophageal (GE) junction cancers. Combination of trastuzumab with cytotoxic chemotherapy has demonstrated a survival advantage in patients with Her2/Neu positive gastric cancer. However, the prognosis of advanced esophagogastric cancer remains poor. This is largely attributed to the tumor heterogeneity and poorly understood tumor biology. This article provides a summary of potential genetic targets and the role of novel targeted agents in the treatment of esophagogastric cancer.

摘要

在过去的十年中，胃食管癌症的治疗方法迅速发展。新的细胞毒性药物和靶向药物已经被整合到治疗模式中。为了更好地了解肿瘤生物学并更好地利用靶向药物，胃食管癌症中的遗传改变得到了积极的探索。例如，在胃癌和胃食管交界处癌症中观察到 Her2/Neu 扩增和表达。曲妥珠单抗联合细胞毒性化疗在 Her2/Neu 阳性胃癌患者中显示出生存优势。然而，晚期胃食管癌症的预后仍然很差。这主要归因于肿瘤异质性和对肿瘤生物学的了解不足。本文提供了潜在遗传靶点的概述以及新型靶向药物在胃食管癌症治疗中的作用。